PedAM
Pediatric Disease Annotations & Medicines
| Disease | breast cancer |
| Symptom | |bone metastases |
| Sentences | 118 |
| PubMedID- 19424729 | Skeletal-related events (sres) in breast cancer patients with bone metastases treated in the nontrial setting. |
| PubMedID- 26237063 | The primary objective of this study is to compare the proportion of high-risk metastatic breast cancer patients with bone metastases that will achieve a decrease in serum c-telopeptide (a surrogate for decreased risk of sres) in the zoledronic and pamidronate treatment arms. |
| PubMedID- 26237064 | Results from a phase 3, randomised, double-blind study comparing denosumab with zoledronic acid for the prevention of skeletal-related events in patients with bone metastases associated with breast cancer . |
| PubMedID- 24403238 | Suvmax and tlg were both predictors of survival in breast cancer patients with bone metastases. |
| PubMedID- 25670024 | A high proportion of breast cancer patients presenting with bone metastases experience significant co-morbidities such as bone fracture and hypercalcemia23. |
| PubMedID- 24389827 | Purpose: the purpose of this paper is to document the use of intravenous (iv) bisphosphonates for prevention of skeletal-related events (sres) in patients with bone metastases (bm) due to breast cancer (bc), lung cancer (lc), or prostate cancer (pc). |
| PubMedID- 22970388 | breast cancer patients with bone metastases may be candidates for treatment with selective pik3ca inhibitors. |
| PubMedID- 24107437 | Background: this qualitative sub-study aimed to explore the experiences of participants on the national cancer research institute zice clinical trial, a randomised trial assessing two types of bisphosphonate treatment in breast cancer patients with bone metastases. |
| PubMedID- 24470767 | Denosumab was evaluated against zoledronic acid in a randomized, double-blind phase 3 clinical study of pain in 2,046 advanced breast cancer patients with bone metastases.28 the authors concluded that denosumab showed improved pain prevention and similar pain palliation when compared with zoledronic acid; also, fewer individuals receiving denosumab transitioned to the use of strong opioid analgesics. |
| PubMedID- 22307370 | Bisphosphonates: prevention of bone metastases in breast cancer. |
| PubMedID- 21309480 | The study showed an apoptosis-mediated cytotoxic effect for ibandronic acid (in addition to the already known osteoclast inhibiting effect) in breast cancer patients with bone metastases; which was also observed in prostate cancer cells. |
| PubMedID- 26237249 | Existing guideline recommendations for bisphosphonate use in metastatic breast cancer patients with bone metastases. |
| PubMedID- 24367175 | Optimal management of bone metastases in breast cancer patients. |
| PubMedID- 23334521 | Purpose: bone metastases occur in 65-75% of patients with metastatic breast cancer. |
| PubMedID- 22162137 | In nude rats bearing bone metastases after injection of mda-mb-231 human breast cancer cells, biodistribution studies were performed to evaluate the accumulation of the radiotracer in selected organs, blood and bone metastases 0.5, 1, 2 and 3 h post injection. |
| PubMedID- 25007963 | A retrospective review was performed on 247 breast cancer patients with bone metastases identified on axial skeleton mri. |
| PubMedID- 26247664 | 12 reported a median survival time of 55.2 months among 110 breast cancer patients with only bone metastases. |
| PubMedID- 21559440 | A therapeutic targeting could help in preventing skeletal related events in breast cancer patients with bone metastases, preserving bone health in patients receiving cancer treatments that induce bone loss (ctibl) and reducing the risk of disease recurrence in adjuvant setting. |
| PubMedID- 25351174 | For example, molecules involved in osteolytic bone metastases (represented with breast cancer) include parathyroid hormone-related protein, transforming growth factor-beta, while in osteoblastic lesions (represented with prostate cancer), endothelin-1 and morphogenetic proteins, etc. |
| PubMedID- 23290478 | Materials and methods: twenty-seven breast cancer patients with bone metastases were prospectively studied with fast dixon-based wb mri including head/neck, chest, abdominal, pelvic, thigh, calf/feet and either cervical, thoracic and lumbar or cervical/thoracic and thoracic/lumbar regions. |
| PubMedID- 24072232 | breast cancer patients with bone metastases only are candidates for effective but low toxic treatment. |
| PubMedID- 26062800 | Immunohistochemical predictors of bone metastases in breast cancer patients. |
| PubMedID- 21498994 | We experienced a case of endocrine therapy-resistant recurrent breast cancer with liver and bone metastases, treated with s-1 as first-line chemotherapy and maintaining a good quality of life. |
| PubMedID- 25731373 | We report the case of an elderly, advanced breast cancer patient with multiple bone metastases. |
| PubMedID- 21224702 | A case of stage iv breast cancer with bone metastases that responded well for long-term to hormonal therapy. |
| PubMedID- 22017235 | Conclusions: this analysis suggests that fewer than half of breast cancer patients with bone metastases receive iv-bps. |
| PubMedID- 23796585 | Methods: thirteen breast cancer patients with multiple painful bone metastases to the lower half of the body were enrolled in this prospective trial. |
| PubMedID- 24673572 | Pharmacotherapy of bone metastases in breast cancer patients--an update. |
| PubMedID- 21665138 | Background: zoledronic acid (za) reduces skeletal complications in breast cancer patients with bone metastases. |
| PubMedID- 21099351 | We have delineated tgfbeta signaling pathways in the production of osteolytic factors interleukin-8 and interleukin-11 in breast cancer cells with different bone metastases potential. |
| PubMedID- 23961251 | On 2046 patients of breast cancer with bone metastases reported denosumab to be superior to zoledronic acid by significantly increasing the time to first on-study sre. |
| PubMedID- 21911478 | We present a previously unreported case of fatal pjp in a breast cancer patient with bone metastases who was receiving a first-line treatment with weekly paclitaxel, trastuzumab, and dexamethasone as premedication for paclitaxel. |
| PubMedID- 23327413 | Results: we selected 109 metastatic breast cancer patients with histologically confirmed bone metastases. |
| PubMedID- 24457902 | This study found that ptx3 expression was up-regulated in distant bone metastases of breast cancer compared to lung, liver, and brain metastases in 64 human breast cancer patients. |
| PubMedID- 22844410 | For these patients, zoledronic acid has emerged as a new drug commonly used for the treatment of bone metastases in patients with breast cancer, and evidence showed that zoledronic acid was the most effective in patients with metastases breast cancer . |
| PubMedID- 22721794 | The current recommended systemic treatment for the prevention of sres is based on the use of bisphosphonates: ibandronate, pamidronate and zoledronic acid- the most potent one- are approved in advanced breast cancer with bone metastases, whereas only zoledronic acid is indicated in advanced prostate cancer with bone metastases. |
| PubMedID- 25646043 | Detection of bone metastases in breast cancer (bc) patients by serum tartrate-resistant acid phosphatase 5b (tracp 5b), a bone resorption marker and serum alkaline phosphatase (alp), a bone formation marker, in lieu of whole body skeletal scintigraphy with technetium99m mdp. |
| PubMedID- 20664592 | In this article the therapeutic response of breast cancer patients with bone metastases was assessed by applying both the new mda response criteria (hamaoka et al, 2004) that are based on computed tomography (ct), magnetic resonance imaging (mri), plain radiography (xr) and skeletal scintigraphy (ss), and the old world health organization (who) response criteria that are based on xr and ss (who, 1979). |
| PubMedID- 22570568 | Based on recent research using population- based and medical registries in denmark, 1- and 3-year cumulative survival in breast cancer patients diagnosed with bone metastases was 59% and approximately 22%,13 respectively. |
| PubMedID- 23269924 | Finally, authors showed that defective irf7 signaling pathway in human breast cancers was significantly associated with bone metastases as the first site of dissemination (bidwell et al., 2012). |
| PubMedID- 24728613 | Thus, there remains a need for treatment to further reduce skeletal complications, improve quality of life, and ultimately extend survival in breast cancer patients with bone metastases. |
| PubMedID- 24932278 | Pain resulting from bone metastases, in patients with breast cancer, may cause an additional emotional and physical burden for those patients (11,12). |
| PubMedID- 25950681 | Za is widely used in the treatment of bone metastases due to breast cancer. |
| PubMedID- 23442322 | Her2 expression is increased in luminal tumors grown in mouse bone xenografts, as well as in bone metastases from patients with breast cancer as compared with matched primary tumors. |
| PubMedID- 26237149 | Zoledronate (4 mg iv, every four weeks) was shown to significantly decrease the fracture rate (25.4% vs. 38.9% for placebo) and lower the incidence of one or more sres (29.8% vs. 49.6% for placebo) among breast cancer patients with bone metastases . |
| PubMedID- 25332877 | Effects of de-escalated bisphosphonate therapy on bone turnover biomarkers in breast cancer patients with bone metastases. |
| PubMedID- 26237148 | Well-known bone-targeted agents, bisphosphonates and the receptor activator of nuclear kappa ligand (rankl) inhibitor, denosumab, have emerged as effective options for the treatment of breast cancer patients with bone metastases . |
| PubMedID- 24009721 | Increased postn serum levels are found in human breast cancer patients with bone metastases , . |
| PubMedID- 23574944 | Going back to the combination of radiotherapy and bisphosphonates, canadian data suggested that use of bisphosphonates has not reduced the utilization rates of palliative radiotherapy in breast cancer patients with bone metastases . |
| PubMedID- 22872842 | Only one patient in the tram-lr group died, which was caused by pericardial effusion after radiation therapy for multiple bone metastases of breast cancer. |